-
Tytuł:
-
Frequency and types of EGFR mutations in Moroccan patients with non-small cell lung cancer.
-
Autorzy:
-
Lemine Sow M; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
El Yacoubi H; Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Moukafih B; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Balde S; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Akimana G; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Najem S; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
El Khoyaali S; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Abahssain H; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Chaibi A; Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Zeb Khan S; Department of Clinical Oncology, BINOR Cancer Hospital, Bannu, Pakistan.
Trapani D; Department of Oncology and Hematology, University of Milan.; Division of New Drug Development, European Institute of Oncology, Milan, Italy.
Benzekri A; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Ghaouti M; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Gamra L; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Mestari A; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Kettani F; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Rahali Y; Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Mrabti H; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Elghissassi I; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
Errihani H; Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.
-
Źródło:
-
Tumori [Tumori] 2021 Aug; Vol. 107 (4), pp. 335-340. Date of Electronic Publication: 2020 Oct 20.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2018- : Thousand Oaks, CA : Sage Publications
Original Publication: Milano : Istituto nazionale per lo studio e la cura dei tumori
-
MeSH Terms:
-
Mutation Rate*
Adenocarcinoma of Lung/*epidemiology
Biomarkers, Tumor/*genetics
Carcinoma, Non-Small-Cell Lung/*epidemiology
Lung Neoplasms/*epidemiology
Adenocarcinoma of Lung/genetics ; Adenocarcinoma of Lung/pathology ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; ErbB Receptors/genetics ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Morocco/epidemiology ; Prognosis ; Retrospective Studies
-
Contributed Indexing:
-
Keywords: EGFR mutation; Lung adenocarcinoma; global oncology; non-small cell lung cancer
-
Substance Nomenclature:
-
0 (Biomarkers, Tumor)
EC 2.7.10.1 (EGFR protein, human)
EC 2.7.10.1 (ErbB Receptors)
-
Entry Date(s):
-
Date Created: 20201020 Date Completed: 20210810 Latest Revision: 20220425
-
Update Code:
-
20240105
-
DOI:
-
10.1177/0300891620964571
-
PMID:
-
33079008
-
Background: Mutations in the epidermal growth factor receptor ( EGFR ) gene are commonly observed in non-small cell lung cancer (NSCLC), particularly in adenocarcinoma histology. The frequency of EGFR mutations is ethnicity-dependent, with a higher proportion reported in Asian populations than Caucasian populations. There is a lack of data on these mutations in north Africa.
Methods: Tumor specimens from Moroccan patients with NSCLC were collected from five pathology laboratories between November 2010 and December 2017 to determine frequency and types of EGFR mutations. Tumors were tested in a reference center for EGFR by polymerase chain reaction and sequencing of exons 18, 19, 20, and 21.
Results: A total of 334 patients were enrolled: 242 (72.5%) males and 92 females (27.5%). A total of 56.9% had a history of smoking. EGFR testing of the 334 lung adenocarcinoma samples demonstrated a wild-type EGFR in 261 (78.1%) and mutated EGFR in 73 (21.9%). Mutations were mainly detected in the exon 19 deletion (65.8%), followed by exon 21 L858 (17.8%) and other exon 21 codon mutations (5.5%) and exon 18 (6.8%), whereas primary mutations of exon 20 were less frequent (4.1%). In patients with advanced NSCLC, the detection of EGFR mutation was independently associated with sex (41.3% female vs 14.5% male; p < 0.001) and smoking status (34.8% nonsmokers vs 12.9% active smokers; p < 0.001). The mean age was significantly different between the two groups ( p = 0.041).
Conclusion: Our findings confirm the genetic heterogeneity of NSCLC worldwide, reporting frequency of EGFR mutations in Moroccan patients with NSCLC between those of Asian and Caucasian populations.